Transient low doses of DNA-demethylating agents exert durable antitumor effects on hematological and epithelial tumor cells. - Wikidata - awgldk - TriplyDB

Transient low doses of DNA-demethylating agents exert durable antitumor effects on hematological and epithelial tumor cells.

Transient low doses of DNA-demethylating agents exert durable antitumor effects on hematological and epithelial tumor cells.

http://www.wikidata.org/entity/Q35851931

about

Turning on the Radio: Epigenetic Inhibitors as Potential Radiopriming Agents Epigenetic therapy in gastrointestinal cancer: the right combination Epigenetics in non-small cell lung cancer: from basics to therapeutics Serine, glycine and one-carbon units: cancer metabolism in full circle New answers to old questions from genome-wide maps of DNA methylation in hematopoietic cells Epigenetic deregulation of microRNAs in rhabdomyosarcoma and neuroblastoma and translational perspectives Mechanisms of disseminated cancer cell dormancy: an awakening field Loss of function of TET2 cooperates with constitutively active KIT in murine and human models of mastocytosis T-cell mediated anti-tumor immunity after photodynamic therapy: why does it not always work and how can we improve it?Epigenetic Therapeutics: A New Weapon in the War Against Cancer Epigenome-based personalized medicine in human cancer Reassembly of nucleosomes at the MLH1 promoter initiates resilencing following decitabine exposure Prolonged treatment with DNMT inhibitors induces distinct effects in promoters and gene-bodies Enhancing the Cytotoxic Effects of PARP Inhibitors with DNA Demethylating Agents - A Potential Therapy for Cancer Epigenetic changes induced by adenosine augmentation therapy prevent epileptogenesis.Sequential treatment with cytarabine and decitabine has an increased anti-leukemia effect compared to cytarabine alone in xenograft models of childhood acute myeloid leukemia.Decitabine: a review of its use in older patients with acute myeloid leukaemia.A phase I study of decitabine with pegylated interferon α-2b in advanced melanoma: impact on DNA methylation and lymphocyte populations.Epigenetic reprogramming modulates malignant properties of human liver cancer.Comprehensive mapping of the effects of azacitidine on DNA methylation, repressive/permissive histone marks and gene expression in primary cells from patients with MDS and MDS-related disease.Combination epigenetic therapy in metastatic colorectal cancer (mCRC) with subcutaneous 5-azacitidine and entinostat: a phase 2 consortium/stand up 2 cancer study.A recombinant reporter system for monitoring reactivation of an endogenously DNA hypermethylated gene.Epigenetic targeting of ovarian cancer stem cells 5-azacytidine reduces methylation, promotes differentiation and induces tumor regression in a patient-derived IDH1 mutant glioma xenograft.Gene body methylation can alter gene expression and is a therapeutic target in cancer.Epigenetic contribution to individual variation in response to lipopolysaccharide in bovine dermal fibroblasts.Acute hypersensitivity of pluripotent testicular cancer-derived embryonal carcinoma to low-dose 5-aza deoxycytidine is associated with global DNA Damage-associated p53 activation, anti-pluripotency and DNA demethylation.Small-molecular modulators of cancer-associated epigenetic mechanisms.The novel, small-molecule DNA methylation inhibitor SGI-110 as an ovarian cancer chemosensitizer.p53 binding to human genome: crowd control navigation in chromatin context Current and upcoming approaches to exploit the reversibility of epigenetic mutations in breast cancer.Age dependent changes in the LPS induced transcriptome of bovine dermal fibroblasts occurs without major changes in the methylome NR2F1 controls tumour cell dormancy via SOX9- and RARβ-driven quiescence programmes.Molecularly targeted therapies in non-small-cell lung cancer annual update 2014 Evaluation of noncytotoxic DNMT1-depleting therapy in patients with myelodysplastic syndromes.Evaluation of azacitidine and entinostat as sensitization agents to cytotoxic chemotherapy in preclinical models of non-small cell lung cancer ZEB1-associated drug resistance in cancer cells is reversed by the class I HDAC inhibitor mocetinostat.Inhibiting DNA Methylation Causes an Interferon Response in Cancer via dsRNA Including Endogenous Retroviruses Consequences of combining siRNA-mediated DNA methyltransferase 1 depletion with 5-aza-2'-deoxycytidine in human leukemic KG1 cells Impact of MLL5 expression on decitabine efficacy and DNA methylation in acute myeloid leukemia.

P2860

Q26744212-FB65D04A-E4A7-4D89-80D3-4112F7B616A3 Q26745709-252D0FA0-2C35-4AB2-A607-0759774EFD28 Q26749113-0F0C91F1-FB2B-4D9B-8BA5-466A3E99C3C7 Q26828610-4B946070-4DF7-48C1-AAD2-DD137A754947 Q26851510-D77DBA07-0222-4886-8B1D-72CCF1F0F6A6 Q26999187-A4EE59E8-7CF7-44B2-BC74-DED7D4F21382 Q27027015-0DEE80E9-50AE-42F7-85D8-AD70768A3236 Q27334940-F0B0622F-4CA5-42AB-A8D9-EDA57D948F16 Q27335110-8CE9B7AF-69AE-40D3-A73F-8355C7C881FA Q28072370-89743B7E-E022-4F21-9BFD-F757EE695142 Q28083951-DB436FE5-D51C-4297-9180-89CFE5048ECB Q28534843-89C06885-1036-4447-AADA-52FCC9F54911 Q28535153-90FB2333-781C-4A23-80C5-93C2B0524057 Q29147555-E86E4675-76E8-49BB-995D-9CEC5A9FB8D6 Q30541877-A5B3F1D2-CA20-44F9-A439-B94EAA74E706 Q31149399-A42091E9-A4FE-463D-B669-9BC74CE78F56 Q33407030-F13ABD5C-8DBC-4122-84BD-52A79CD123AC Q33415592-B6953A54-5228-4EDA-A08E-BCF5523AFF76 Q33707196-7979BAEF-F715-46E6-9C31-B311CBA8024F Q33709905-4629831E-B0F2-43B8-A7B2-517E08CA144A Q33798842-43B6D56A-5A42-42A8-90BF-8D7B26F356EF Q33918412-5AC41A53-50A5-40CB-8373-49410012F06A Q34135466-B0AD38EB-535D-4655-A767-71EC8CD0DCD4 Q34374136-56FFD4B0-91DC-4AF3-AC5B-58D45E42B859 Q34471361-9A1E2B1D-D217-4AA2-B7E4-C9DF6696C5D1 Q34495727-1CE62CE3-922A-4840-93E3-8FDEFCFCB442 Q34541513-C8DD9A26-E3FC-4AB9-89B4-6B834A70357A Q34628002-0060D763-1435-4F77-B211-CE9CC918B283 Q34717933-A6F5244D-D819-4ED8-AE53-0449EE1D8578 Q34755812-2CE2785E-BB51-41A8-9F85-EF56AE2040BA Q35000789-D5F6D2B4-B914-410C-9B9A-F2DF739982FA Q35033454-B105AB3A-0112-4D07-83F6-56A7400E60CC Q35037151-4AA2372D-E5AE-4E17-AC90-099BA3691976 Q35136424-895663EC-FCC8-4EA4-BAB0-1F86D1178452 Q35183982-6E285D44-C624-4174-8018-61995F65CF70 Q35238397-A12160F4-4E81-44F3-B553-7FC2455C9D22 Q35695410-9EBD061D-A370-40E6-A2B9-FC8FF32BE9AF Q36015063-488DE8A2-4346-4DB2-8291-824C9A0F6553 Q36020996-D506912C-2303-4301-96BD-9ACA32383B74 Q36036304-AB82B5B9-A500-4071-8EE5-2E7F57704A55

P2860

Transient low doses of DNA-demethylating agents exert durable antitumor effects on hematological and epithelial tumor cells.

http://www.wikidata.org/entity/Q35851931

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

2012年论文

@zh

2012年论文

@zh-cn

name

Transient low doses of DNA-dem ...... al and epithelial tumor cells.

@ast

Transient low doses of DNA-dem ...... al and epithelial tumor cells.

@en

type

label

Transient low doses of DNA-dem ...... al and epithelial tumor cells.

@ast

Transient low doses of DNA-dem ...... al and epithelial tumor cells.

@en

prefLabel

Transient low doses of DNA-dem ...... al and epithelial tumor cells.

@ast

Transient low doses of DNA-dem ...... al and epithelial tumor cells.

@en

P1433

Q35851931-90B095F5-5453-465C-8FC3-4914E5B2290D

P1476

Q35851931-BB7E388B-3482-4D8A-AD4C-B53BECD0E107

P2093

Q35851931-06769F65-E94A-48BA-8A07-6F8CDA0911E3

Q35851931-09BBB871-AA14-42F6-A35E-4ED4FE960B82

Q35851931-0A4B05E8-2CF8-4861-9A94-AD84641C2355

Q35851931-1384FA79-CFB7-4D03-8D3C-FEDBB86ECCED

Q35851931-17F848FD-449F-44A1-9382-4E4AAF2853CF

Q35851931-4275A8A0-1900-4375-BB79-753BA8DDFA38

Q35851931-62955312-4091-4888-92E0-5E58BA112AFB

Q35851931-69A16E64-89AD-4D22-8CE5-DB894126D488

Q35851931-6F8684BD-037B-465C-B718-88788EB47939

Q35851931-73BED83E-465F-4E65-9276-EE741E18EAEE

P2860

Q35851931-011D1A72-93FE-4C20-BCDD-77D5E1363E05

Q35851931-0B0FE85F-0078-492E-BAF6-076854A37592

Q35851931-10F739BB-A952-4F45-9D70-10FECF36C2D8

Q35851931-18F06EC8-6EB4-4674-AD40-26F71482FE8A

Q35851931-23D5EBF4-6DAB-4960-AF23-1860903C5B53

Q35851931-253BC58E-5BB3-466F-86BF-60129F622247

Q35851931-25683429-DD85-4C9F-9D29-4AB0720631A6

Q35851931-3190127F-73BB-4E3E-B57B-20D4E7DB4A7B

Q35851931-31E53CAD-F71B-4813-BA8A-9AE5915B6185

Q35851931-3731A2EE-FB32-4327-9809-ACBC339B802D

P304

Q35851931-BAD7E71B-86EE-4341-B7A6-5DFDC55E259D

P31

Q35851931-587633C0-CC79-42E9-99FC-B753693550D2

P356

Q35851931-732A8F95-7142-4B7C-8ECC-C390FF10BCFC

P433

Q35851931-29412D7C-A1AA-43E6-9E41-715967663120

P478

Q35851931-21B141C7-9BFA-4412-8DA6-6EA62C7ACC48

P50

Q35851931-0DAC09C2-09E6-4465-BD00-FFDE04AE0D81

Q35851931-CA130B3B-7176-41C0-A52C-8CE1D32EC7C8

P577

Q35851931-5C62EAE1-9B20-43E9-BD51-4388850216F5

P5875

Q35851931-A2AFAC2A-A16A-4438-8534-A57720CACD90

P698

Q35851931-58C8D63B-73C7-467C-B049-7CBFDE936723

P932

Q35851931-215CA2EC-90B0-49C7-8F9C-CBC39B6D9EEB

P356

J.CCR.2011.12.029

P1433

P1476

Transient low doses of DNA-dem ...... al and epithelial tumor cells.

@en

P2093

Alana L Welm

http://www.w3.org/2001/XMLSchema#string

Carine Robert

http://www.w3.org/2001/XMLSchema#string

Cynthia A Zahnow

http://www.w3.org/2001/XMLSchema#string

Emmanouil Pappou

http://www.w3.org/2001/XMLSchema#string

Feyruz V Rassool

http://www.w3.org/2001/XMLSchema#string

Hsing-Chen Tsai

http://www.w3.org/2001/XMLSchema#string

Huili Li

http://www.w3.org/2001/XMLSchema#string

Il Minn

http://www.w3.org/2001/XMLSchema#string

James Harris

http://www.w3.org/2001/XMLSchema#string

James J Shin

http://www.w3.org/2001/XMLSchema#string

P2860

Hallmarks of Cancer: The Next Generation

DNMT1 binds HDAC2 and a new co-repressor, DMAP1, to form a complex at replication foci

Identification of cells initiating human melanomas

Tumor grafts derived from women with breast cancer authentically reflect tumor pathology, growth, metastasis and disease outcomes

ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome

Prospective identification of tumorigenic breast cancer cells

Identification and expansion of human colon-cancer-initiating cells

A human colon cancer cell capable of initiating tumour growth in immunodeficient mice

Identification of human brain tumour initiating cells

A cell initiating human acute myeloid leukaemia after transplantation into SCID mice

P304

430-446

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.CCR.2011.12.029

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

21

http://www.w3.org/2001/XMLSchema#string

P50

David Feller-Kopman

P577

2012-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

221968773

http://www.w3.org/2001/XMLSchema#string

P698

22439938

http://www.w3.org/2001/XMLSchema#string

P932

3312044

http://www.w3.org/2001/XMLSchema#string